期刊
CLINICS IN CHEST MEDICINE
卷 32, 期 4, 页码 853-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2011.07.002
关键词
Small cell lung cancer; Limited stage; Advanced stage; Chemotherapy
资金
- Genentech
- Celgene
- Novartis
- Pfizer
Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15%. Extensive stage disease has initial response rates to chemotherapy exceeding 70%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy back-bone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据